| Valuation studies? Our collective two cents H Kjellberg, A Mallard, DL Arjaliès, P Aspers, S Beljean, A Bidet, A Corsin, ... Valuation Studies 1 (1), 11, 2013 | 143 | 2013 |
| The Q (u) ALYfying hand: Health economics and medicine in the shaping of Swedish markets for subsidized pharmaceuticals E Sjögren, CF Helgesson The Sociological Review 55 (2_suppl), 215-240, 2007 | 86 | 2007 |
| Valuation studies and the critique of valuation L Doganova, M Giraudeau, CF Helgesson, H Kjellberg, F Lee, A Mallard, ... Valuation Studies 2 (2), 87-96, 2014 | 53 | 2014 |
| Reasonable drugs: Making decisions with ambiguous knowledge E Sjögren Economic Research Institute, Stockholm School of Economics (EFI)., 2006 | 37 | 2006 |
| Valuation and Calculation at the Margins A Mennicken, E Sjögren Valuation Studies 3 (1), 1-7, 2015 | 32 | 2015 |
| ‘Accounting Talk’ Through Metaphorical Representations: Change Agents and Organisational Change in Home-Based Elderly Care M Carlsson-Wall, K Kraus, M Lund, E Sjögren European Accounting Review 25 (2), 215-243, 2016 | 27 | 2016 |
| Glocal Pharma E Johnson, E Sjögren, C Åsberg Taylor & Francis, 2016 | 15 | 2016 |
| More Knowledge, Better Government? Consequences of Knowledge‐Based Decision Making in Swedish Pharmaceutical Benefits ÅC Vifell, E Sjögren Governance 24 (1), 85-110, 2011 | 15 | 2011 |
| Identifying need through expressions of demand: Deciding on public financial intervention within the fields of healthcare and development aid A Krohwinkel-Karlsson, E Sjögren Routledge 10 (2), 197-220, 2008 | 11 | 2008 |
| The legal mind of the internal market: A governmentality perspective on the judicialization of monitoring practices ÅC Vifell, E Sjögren JCMS: Journal of Common Market Studies 52 (3), 461-478, 2014 | 10 | 2014 |
| Deciding subsidy for pharmaceuticals based on ambiguous evidence E Sjögren Journal of Health, Organisation and Management 22 (4), 368-383, 2008 | 9 | 2008 |
| Decision usefulness explored: An investigation of capital market actors' use of financial reports A Hjelstrom, T Hjelstrom, E Sjogren Stockholm, Svenskt Naringsliv, 2014 | 8 | 2014 |
| Defining ‘markets’ for pharmaceuticals in Sweden: Public policy and commercialization E Sjogren Minerva 45 (2), 161-173, 2007 | 7 | 2007 |
| No finish line: How formalization of academic assessment can undermine clarity and increase secrecy KS Helgesson, E Sjögren Gender, Work and Organization 26 (4), 558-581, 2019 | 5 | 2019 |
| Democratic priority-setting? Organizing multiple stakeholders to make decisions in the healthcare sector E Sjögren, K Fernler L. Sonderyd, G. Sundström and S. Furusten, Organizing Democracy: The …, 2010 | 5 | 2010 |
| Reasonable drugs E Sjögren Making Decisions with Ambiguous Knowledge, 2006 | 5 | 2006 |
| Role attribution in public sector accountability processes: Dynamic and situation-specific accountor and constituent roles E Hagbjer, K Kraus, J Lind, E Sjögren Qualitative Research in Accounting & Management, 2017 | 4 | 2017 |
| Trust in the Monitoring of Publicly Funded Services: A Case Study of Two Outsourced Care Homes for the Elderly E Hagbjer, J Lind, E Sjögren Trust and Organizations, 147-164, 2013 | 4 | 2013 |
| Prescribing for the “Swedish Viagra Man” E Johnson, E Sjögren, C Åsberg Clinical pharmacology and therapeutics 89 (1), 15, 2011 | 4 | 2011 |
| Five years! Have we not had enough of valuation studies by now? L Doganova, M Giraudeau, H Kjellberg, CF Helgesson, F Lee, A Mallard, ... Valuation Studies 5 (2), 83-91, 2018 | 3 | 2018 |
